NCT01728805 2024-04-25Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLKyowa Kirin Co., Ltd.Phase 3 Completed372 enrolled 14 charts 1 FDA
NCT00958074 2018-10-18Vorinostat in Patients With Primary Cutaneous T-Cell LymphomaUniversity of WashingtonPhase 2 Terminated11 enrolled 11 charts
NCT01187446 2017-11-20Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis FungoidesStanford UniversityPhase 1/2 Terminated28 enrolled 13 charts
NCT00601718 2017-05-25Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaUniversity of WashingtonPhase 1/2 Completed29 enrolled 10 charts